MRNA
HOLD / NEUTRALMeanRevComposite
45.20
Technical
95.50
Fundamental
28.50
Rank
—
Price
154.27
Hurst
0.08
As of
Sep 2, 2026
DailyTurtleMean-reversionbiotech · IMPROVING
Moderna, Inc.
HealthcareBiotechnologyModerna develops and sells messenger RNA-based treatments across multiple disease areas including respiratory infections, latent viral infections, and cancer. The company's pipeline spans vaccines for conditions like COVID-19, RSV, and influenza, alongside therapeutic programs targeting oncology and rare genetic disorders. Based in Cambridge, Massachusetts, Moderna partners with major pharmaceutical companies and government health organizations to advance its research and development efforts.
Market cap
$63.1B
P/E (trailing)
—
P/E (forward)
-35.37
PEG ratio
—
Dividend yield
—
Beta
1.11
52w range
22.28 – 176.66
Return on equity
-39.00%
Profit margin
-141.43%
Revenue growth
+2.10%
Earnings growth
—
Price history
1Y: 158.07 (+521.1%) · range 22.36–174.38
Cycle position
89/ 100 cycle scoreEXIT ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 0 · NOT READY · exit proximity 90
Conviction
31/ 100 · maturity 100%
VScore.4048
Buildup.2035
EMA entry setup.250
Fundamentals.1529
Volume profile
POC
47.67
Price vs POC
+231.6%
Overhead supply
6%
Runway
open sky
Value area 43.68–144.74 · 6% of 120d volume overhead · clean runway
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| trend-signal | 1.000 | Sep 17, 2026 |
| short-interest | 0.664 | Sep 14, 2026 |
| squeeze-risk | 0.559 | Sep 14, 2026 |
| forum-chatter | 0.331 | Sep 17, 2026 |
Pattern & cluster
Pattern
none
Cluster
IMPROVING · rank 12 · inflow
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +5.38% | +5.38% | 1/20d |
| 40d | +5.38% | +5.38% | 1/40d |